Table 2 Included studies (N = 46)
First Author | N | Diagnosis | Drugs | Country | Setting | Start date | End date |
|---|---|---|---|---|---|---|---|
Alpuente 2021 [38] | 263 | EM and CM | Erenumab, Galcanezumab | Spain | Monocentric | February 2019 | February 2021 |
Alpuente 2021 [39] | 155 | CM | Erenumab, Galcanezumab | Spain | Monocentric | NA | NA |
Altamura 2022 [40] | 155 | EM and CM | Galcanezumab | Italy | Multicentric | September 2019 | December 2021 |
Barbanti 2019 [42] | 78 | EM and CM | Erenumab | Italy | Monocentric | 20 December 2018 | 7 March 2019 |
Barbanti 2020 [43] | 372 | EM and CM | Erenumab | Italy | Multicentric | December 2018 | September 2019 |
Barbanti 2021 [41] | 242 | EM and CM | Erenumab | Italy | Multicentric | December 2018 | July 2020 |
Barbanti 2022 [44] | 53 | EM and CM | Fremanezumab | Italy | Multicentric | July 2020 | November 2020 |
Becker 2022 [45] | 95 | EM and CM | Erenumab | Canada | Multicentric | April 2019 | April 2020 |
Belvis 2021 [46] | 210 | EM and CM | Erenumab | Spain | Multicentric | February 2019 | June 2020 |
Caronna 2021 [47] | 139 | CM | Erenumab | Spain | Monocentric | February 2019 | April 2021 |
Cetta 2022 [48] | 30 | EM and CM | Erenumab | Italy | Monocentric | February 2019 | January 2022 |
Cheng 2020 [49] | 170 | CM | Erenumab | Australia | Multicentric | October 2018 | April 2020 |
Cullum 2022 [50] | 300 | CM | Erenumab | Denmark | Monocentric | January 2019 | February 2020 |
Curone 2020 [51] | 27 | CM | Erenumab | Italy | Monocentric | NA | NA |
Curone 2022 [52] | 303 | CM | Erenumab, Galcanezumab, Fremanezumab | Italy | Monocentric | October 2020 | September 2021 |
De Icco 2022 [53] | 77 | CM | Erenumab | Italy | Monocentric | December 2018 | January 2020 |
De Matteis 2021 [54] | 32 | EM and CM | Erenumab | Italy | Multicentric | December 2019 | October 2020 |
de Vriesch Lentsch 2021 [55] | 100 | EM and CM | Erenumab | The Netherlands | Monocentric | January 2019 | March 2020 |
Gonzalez-Martinez 2022 [56] | 712 | EM and CM | Erenumab, Galcanezumab, Fremanezumab | Spain | Multicentric | November 2018 | August 2021 |
Guerzoni 2022 [57] | 185 | CM | Erenumab | Italy | Multicentric | NA | NA |
Iannone 2022 [59] | 44 | CM | Erenumab, Galcanezumab | Italy | Monocentric | December 2019 | June 2020 |
Iannone 2022 [58] | 203 | CM | Erenumab, Galcanezumab, Fremanezumab | Italy | Monocentric | December 2019 | April 2021 |
Krymchantowski 2022 [60] | 112 | EM and CM | Erenumab, Galcanezumab, Fremanezumab | Brazil | Multicentric | February 2020 | March 2021 |
Kwon 2022 [61] | 92 | EM and CM | Galcanezumab | South Korea | Monocentric | June 2020 | April 2021 |
Lambru 2020 [62] | 164 | CM | Erenumab | United Kingdom | Monocentric | October 2018 | September 2019 |
Lowe 2022 [63] | 103 | CM | Erenumab | United Kingdom | Monocentric | March 2020 | December 2020 |
Mahovic 2022 [64] | 57 | CM | Erenumab | Croatia | Monocentric | March 2019 | November 2019 |
Matteo 2020 [65] | 159 | EM and CM | Erenumab | Italy | Monocentric | May 2019 | April 2020 |
Pensato 2020 [68] | 39 | CM | Erenumab | Italy | Monocentric | May 2019 | May 2020 |
Pensato 2021 [66] | 149 | CM | Erenumab | Italy | Multicentric | May 2019 | May 2020 |
Pensato 2022 [67] | 111 | CM | Erenumab, Galcanezumab | Italy | Multicentric | April 2019 | November 2020 |
Raffaelli 2022 [69] | 39 | EM and CM | Erenumab, Galcanezumab, Fremanezumab | Germany | Monocentric | NA | NA |
Raffaelli 2022 [70] | 62 | EM and CM | Erenumab, Galcanezumab, Fremanezumab | Germany | Monocentric | January 2020 | November 2020 |
Ranieri 2020 [71] | 30 | EM and CM | Erenumab | Italy | Monocentric | April 2019 | May 2020 |
Russo 2020 [72] | 70 | CM | Erenumab | Italy | Monocentric | February 2019 | July 2019 |
Saeed 2022 [73] | 90 | EM and CM | Erenumab | NA | Monocentric | NA | NA |
Silvestro 2022 [74] | 43 | EM and CM | Galcanezumab | Italy | Multicentric | January 2021 | June 2021 |
Terhart 2021 [75] | 61 | EM and CM | Erenumab, Galcanezumab, Fremanezumab | Germany | Monocentric | January 2020 | December 2020 |
Torres-Ferrus 2021 [76] | 155 | EM and CM | Erenumab | Spain | Monocentric | February 2019 | October 2020 |
Tziakouri 2021 [77] | 16 | CM | Erenumab | Cyprus | Monocentric | NA | NA |
Vernieri 2020 [78] | 81 | EM and CM | Galcanezumab | Italy | Multicentric | NA | July 2020 |
Vernieri 2021 [79] | 156 | CM | Galcanezumab | Italy | Multicentric | November 2019 | January 2021 |
Vernieri 2021 [80] | 163 | EM and CM | Galcanezumab | Italy | Multicentric | November 2019 | January 2021 |
Vernieri 2021 [82] | 154 | EM and CM | Erenumab, Galcanezumab | Italy | Multicentric | November 2019 | July 2021 |
Vernieri 2022 [81] | 191 | EM and CM | Galcanezumab | Italy | Multicentric | September 2019 | November 2021 |
Zecca 2022 [83] | 110 | EM and CM | Erenumab | Switzerland | Multicentric | December 2019 | September 2020 |